期刊文献+

蜂毒素对人肝癌细胞中HMGB1及VEGF-C表达的影响 被引量:1

Effect of melittin on high mobility group box 1 and vascular endothelial growth factors C expressions in hepatocarcinoma cells
在线阅读 下载PDF
导出
摘要 目的观察蜂毒素对人肝癌细胞株HepG2中高迁移率族蛋白B1(high mobility group box1,HMGB1)及血管内皮生长因子C(vascular endothelial growth factors C,VEGF-C)表达的影响,探讨其抑制肝癌细胞的作用机制。方法肝癌细胞HepG2体外培养,经蜂毒素处理后,采用四甲基偶氮唑蓝(MTT)法了解蜂毒素对肝癌细胞增殖的影响,用Western-blotting、qRT-PCR方法检测HMGB1、VEGF-C的表达。结果蜂毒素在体外能够抑制肝癌细胞的增殖活性;Western-blotting结果显示,蜂毒素可抑制HMGB1的表达,且呈浓度依赖性,但对VEGF-C的蛋白表达无明显影响;qRT-PCR结果显示,蜂毒素在mRNA水平均具有抑制HMGB1、VEGF-C表达的作用。结论蜂毒素可降低肝癌细胞的增殖活性,并可能通过HMGB1、VEGF-C的表达发挥抗肝癌作用。 Objective To observe the effect of melittin on the expressions of high mobility group box 1(HMGB1) and vascular endothelial growth factors C(VEGF-C) in hepatocarcinoma cells in vitro and to study the mechanisms of melittin in hepatocarcinoma cells.Methods HepG2 cell line was treated with melittin in vitro.The inhibition of proliferation was detected by MTT assay.The expressions of HMGB1 and VEGF-C were detected by western-blotting and real-time quantitative PCR(qRT-PCR) assay.Results Melittin inhibited cell proliferation in vitro.Western-blotting outcome showed that melittin could down-regulate the protein of HMGB1,while VEGF-C expression did not change.qRT-PCR results showed that HMGB1 and VEGF-C mRNA expressions were down-regulate by melittin.Conclusion It is suggested that melittin can inhibit hepatocarcinoma cells proliferation.The effect of melittin in inducing anti-hepatocarcinoma may be related with down-regulation of HMGB1 and VEGF-C.
出处 《东南国防医药》 2012年第2期101-104,共4页 Military Medical Journal of Southeast China
基金 国家自然科学基金资助项目(30901986) 上海市晨光计划资助项目(10CG41) 南京军区医学科技创新课题项目(10MA028)
关键词 蜂毒素 肝细胞癌 高迁移率族蛋白B1 血管内皮生长因子C melittin hepatocarcinoma HMGB1 VEGF-C
  • 相关文献

参考文献16

  • 1Or(s)olie N. Bee venom in cancer therapy[J].Cancer and Metastasis Review,2011.1-22.
  • 2Jo M,Park MH,Kollipara PS. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway[J].Toxicology and Applied Pharmacology,2012,(01):72-81.doi:10.1016/j.taap.2011.10.009.
  • 3Chen KF,Tai WT,Liu TH. Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3[J].Clinical Cancer Research,2010,(21):5189-5199.doi:10.1158/1078-0432.CCR-09-3389.
  • 4Ohmori H,Luo Y,Kuniyasu H. Non-histone nuclear factor HMGB1 as a therapeutic target in colorectal cancer[J].EXPERT OPINION ON THERAPEUTIC TARGETS,2011,(02):183-193.doi:10.1517/14728222.2011.546785.
  • 5Kokkola B,Andersson A,Mullins G. RAGE is the major receptor for the proinflammatory activity of HMGBI in rodent macrophages[J].Scandinavian Journal of Immunology,2005,(01):1-9.
  • 6Staeker SA,Caesar C,Baldwin ME. VEGF-D promotes the metastatic spread of tumor cella via the lymphatics[J].Nature Medicine,2001,(04):186-191.
  • 7Sparvero LJ,Asafu-Adjei D,Kang R. RAGE (Receptor for Advanced Glycation Endproducts),RAGE ligands,and their role in cancer and inflammation[J].Journal of Traditional Medicines,2009.17.doi:10.1186/1479-5876-7-17.
  • 8Kostova N,Zlateva S,Ugrinova I. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors[J].Molecular and Cellular Biochemistry,2010,(1-2):251-258.doi:10.1007/s11010-009-0305-0.
  • 9Cheng BQ,Jia CQ,Liu CT. Serum high mobility group box chromosomal proteinlis associated with clinicopathologic features in patients with hepatocellular carcinoma[J].Digestive and Liver Disease,2008,(06):446-452.doi:10.1111/j.1708-8305.2011.00558.x.
  • 10Su JL,Shih JY,Yen ML. Cyclooxygenase-2 induces EP1-and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation:a novel mechanism of lymphangiogenesis in lung adenocarcinoma[J].Cancer Research,2004,(02):554-564.

二级参考文献45

  • 1王金胜,冯德云,彭劲武,曾庆富.血管内皮生长因子C在甲状腺癌组织中的表达及其意义[J].实用癌症杂志,2004,19(4):375-376. 被引量:3
  • 2程艳云,王付增,李翠英,程存拴,何琼琼.微血管密度及PCNA在子宫颈鳞癌中表达的临床意义[J].中国医师杂志,2005,7(1):8-10. 被引量:1
  • 3彭扬,张锦,李莉,孟馨,王涤非,周一军,侯率.糖基化终产物促进U937巨噬细胞高密度脂蛋白受体的表达[J].中国动脉硬化杂志,2005,13(2):151-154. 被引量:3
  • 4许子亮,韩中朝.VEGF与血液学恶性疾病[J].国际病理科学与临床杂志,2006,26(4):318-320. 被引量:8
  • 5Tatsuya T, Takchisa H, Kciichiro K, et al. Lymphaticspreading pattern of intrahcpati~ cholangiocarcinoma [J]. Surgery, 2001, 129 (4):401- 407.
  • 6Mayer CG, Penn I, James L, et al. Liver transplantation for cholangioc- arcinoma: results in 207 patients [J].Transplantation, 2000, 69 (8) : 1633-1637.
  • 7Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk fac- tors, and pathogenesis of cholangiocarcinoma [J]. HBP, 2008, 10 (2): 77-82.
  • 8Arigami T, Natsugoe S, Uenosono Y, et al. Vascular endothelial growth factor-C and -D expression correlates with lymph node micrometastasis in pN0 early ICC [J]. J Surg Oncol. 2009, 99 (3): 148-153.
  • 9Miyata Y, Kanda S, Ohba K, et al. Lymphangiogenesis and angiogenes- is in bladder cancer: prognostic implications and regulation by vascular en-dothelial growth factors-A, -C, and -D [J]. Clin Cancer Res, 2006, 12(3 Pt 1):800-806.
  • 10Bando H, Weich HA, Horiguchi S, et al. The association between vasc- ular endothelial growth factor-C, its corresponding receptor, VEGFR-3 and prognosis in primary breast cancer: A study with 193 cases [J] Oncol Rep, 2006,15(3):653-659.

共引文献13

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部